We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aquestive Therapeutics (AQST - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aquestive Therapeutics is one of 978 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Aquestive Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AQST's full-year earnings has moved 0.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that AQST has returned about 12.6% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -4.9% on a year-to-date basis. This means that Aquestive Therapeutics is performing better than its sector in terms of year-to-date returns.
Arbutus Biopharma (ABUS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 3.1%.
The consensus estimate for Arbutus Biopharma's current year EPS has increased 15.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Aquestive Therapeutics is a member of the Medical - Drugs industry, which includes 153 individual companies and currently sits at #84 in the Zacks Industry Rank. On average, this group has gained an average of 8.3% so far this year, meaning that AQST is performing better in terms of year-to-date returns.
Arbutus Biopharma, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 488-stock industry is ranked #146. The industry has moved +2.8% so far this year.
Investors with an interest in Medical stocks should continue to track Aquestive Therapeutics and Arbutus Biopharma. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aquestive Therapeutics (AQST - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aquestive Therapeutics is one of 978 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Aquestive Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AQST's full-year earnings has moved 0.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that AQST has returned about 12.6% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -4.9% on a year-to-date basis. This means that Aquestive Therapeutics is performing better than its sector in terms of year-to-date returns.
Arbutus Biopharma (ABUS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 3.1%.
The consensus estimate for Arbutus Biopharma's current year EPS has increased 15.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Aquestive Therapeutics is a member of the Medical - Drugs industry, which includes 153 individual companies and currently sits at #84 in the Zacks Industry Rank. On average, this group has gained an average of 8.3% so far this year, meaning that AQST is performing better in terms of year-to-date returns.
Arbutus Biopharma, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 488-stock industry is ranked #146. The industry has moved +2.8% so far this year.
Investors with an interest in Medical stocks should continue to track Aquestive Therapeutics and Arbutus Biopharma. These stocks will be looking to continue their solid performance.